Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Dachau – page 87

1 447 clinical trials in Dachau, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dachau at a glance
1 447
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 447 trials in Dachau

Open in trial search

Study Comparing Sotorasib and Panitumumab with Other Drug Combinations for Patients with Metastatic Colorectal Cancer and KRAS p.G12C Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Amgen Inc.

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Insomnia

Not recruiting

Study to Determine Safe and Effective Dose of Daridorexant for Treating Insomnia in Children and Adolescents Aged 10 to 18 Years

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Daridorexant
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Study of Bemarituzumab with Irinotecan, Paclitaxel, Ramucirumab, or Trifluridine/Tipiracil for Advanced Stomach or Gastroesophageal Cancer in Patients After Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Renal cell carcinoma

Not recruiting

Study on Atezolizumab and Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Tumor Progression Post-Immune Checkpoint Inhibitor Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Rectal cancer

Not recruiting

Study Comparing FOLFOX Before Surgery to Risk-Adapted Chemotherapy After Surgery for Patients with Locally Advanced Rectal Cancer and Low Risk of Local Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Heidelberg University

Study of Venetoclax and Blinatumomab for Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Goethe University Frankfurt

Study of Prednisolone and SPI-62 for Patients with Polymyalgia Rheumatica

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clofutriben
  • Sponsor:Sparrow Pharmaceuticals Inc.

Brain neoplasm

Not recruiting

Safety Study of 5-Aminolevulinic Acid for Brain Tumor Surgery in Children and Adolescents

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Aminolevulinic Acid Hydrochloride
  • Sponsor:Universitaet Muenster

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Dachau

What the registry says about research in the country

01 Respiratory Medicine

Research focusing on respiratory syncytial virus (RSV) and chronic obstructive pulmonary disease, evaluating innovative treatment approaches and preventive measures.

  • RSV vaccination studies in older adults
  • COPD treatment optimization
  • Respiratory therapy combinations

Advanced trials investigating both preventive vaccines and therapeutic interventions for respiratory conditions.

02 Gastroenterology

Comprehensive studies addressing inflammatory bowel diseases, including breakthrough treatments for ulcerative colitis and Crohn's disease.

  • Novel therapeutic approaches for UC
  • Crohn's disease management
  • Combination therapy investigations

Multiple innovative treatments being evaluated to improve patient outcomes in inflammatory bowel conditions.

03 Cardiovascular Medicine

Critical research in atrial fibrillation and related cardiovascular conditions, exploring new therapeutic strategies and prevention methods.

  • Cardioembolic event prevention
  • Acute coronary syndrome management
  • Anticoagulation therapy optimization

Innovative approaches to cardiac care and stroke prevention in high-risk patients.

04 Hematology

Advanced research in chronic lymphocytic leukemia, particularly focusing on high-risk patients with specific genetic markers.

  • Triple combination therapy evaluation
  • Treatment of high-risk CLL
  • Novel therapeutic approaches

Cutting-edge treatments targeting specific genetic mutations in blood disorders.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.